Results 241 to 250 of about 41,938 (307)

Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort. [PDF]

Br J Haematol
Noveihed A, Al Hadidi S, Mohan M, Shah MR.   +3 more
europepmc   +1 more source

Discrepant Intracranial and Extracranial Responses to Tarlatamab in Relapsed Small‐Cell Lung Cancer With Untreated Brain Metastases: A Case Report

Respirology Case Reports, Volume 14, Issue 5, May 2026.
A 72‐year‐old man with extensive‐stage SCLC developed untreated brain metastases and was treated with tarlatamab before whole‐brain irradiation. After one cycle, marked shrinkage of extracranial lesions and decreases in tumour markers were observed. By contrast, brain MRI showed progression of intracranial metastases.
Eri Hayashi, Hirohisa Kano, Kayo Nakamura, Takamasa Kondo, Akira Nishioka, Manaya Tanaka, Kotaro Aoe, Shuko Mashimo, Daizo Kishino   +8 more
wiley   +1 more source

Design and development of a bispecific antibody targeting BAFF and IL-17 for systemic lupus erythematosus treatment. [PDF]

BMC Biol
Xin C, Zhou J, Chen Y, Liu Y, Liu H, Liang C, Zhu X, Qi Y, Zhang G, Wang A.   +9 more
europepmc   +1 more source

Aptamer‐Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap

Small Science, Volume 6, Issue 5, May 2026.
Aptamer‐functionalized nanocarriers represent a versatile platform for targeted therapy in bone and joint diseases. This review presents five complementary design strategies: free aptamers for soluble targets, bispecific multivalent constructs for enhanced avidity, nanoparticle‐conjugated aptamers for selective tissue accumulation, aptamer‐based ...
Hamdi Al‐Azzani, Djandan Tadum Arthur Vithran, Syeda Sundas Batool, Malek Mohammed Ali Alshabi, Wenhu Zhou, Xiaoqiang Mao   +5 more
wiley   +1 more source

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer. [PDF]

J Transl Med
Greiner SM, Mauermann J, Lutz MS, Hagelstein I, Hartkopf AD, Zekri L, Jung G, Salih HR, Märklin M.   +8 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Physicochemical and biological characterization of a bispecific antibody in a CrossMab/KIH format that targets EGFR and VEGF-A. [PDF]

Front Immunol
Ayinde S, Dutta S, Mohan N, Wu WJ.
europepmc   +1 more source

Transcriptional Reinforcement of the HER2–RAS Network in HER2‐Positive Gastric Cancer: The RUNX–SOS1 Axis in Context

Cancer Science, Volume 117, Issue 5, Page 1235-1243, May 2026.
RUNX‐dependent transcriptional control of SOS1 reinforces HER2–RAS signaling and may attenuate responses to HER2‐targeted therapies in HER2‐positive gastric cancer. ABSTRACT HER2‐positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral ...
Tatsuya Masuda, Takayoshi Watanabe, Toshinori Ozaki, Yasuhiko Kamikubo   +3 more
wiley   +1 more source

A novel bispecific antibody targeting TNF-α and IL-6 receptor as a potent immunotherapeutic agent for inflammation. [PDF]

Appl Microbiol Biotechnol
Heravi M, Damough S, Mafakher L, Talebkhan Y, Nematollahi L, Ghazizadeh L, Ajdari S.   +6 more
europepmc   +1 more source

A bispecific antibody targeting PD-L1/TNFR2 increases tumor targeting and enhances antitumor efficacy in colorectal cancer. [PDF]

J Immunother Cancer
Kang X, Qian P, Han Y, Wu M, Li Y, Xu C, Wei J.   +6 more
europepmc   +1 more source